Literature DB >> 19813078

Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri.

Benjamin M Ellingson1, Scott D Rand, Mark G Malkin, Kathleen M Schmainda.   

Abstract

Diffusion-weighted magnetic resonance imaging (DWI) is a sensitive imaging biomarker for tumor cellularity. Functional diffusion maps (fDMs), which examine voxel-by-voxel changes in the apparent diffusion coefficient (ADC) calculated from serial DWIs, have previously been applied to regions of contrast-enhancement; however, application of fDMs to non-enhancing brain tumors has not been pursued. In this case study we demonstrate the utility of applying fDMs to regions of abnormal FLAIR signal intensity in a patient diagnosed with gliomatosis cerebri: a relatively rare, infiltrative, non-enhancing brain tumor. The absolute volume of hypercellularity extracted from fDMs was useful in tracking tumor growth, which correlated in time with a progressive decline in neurological status despite no change in traditional magnetic resonance images. Results of this study demonstrate the value of fDMs, applied to regions of FLAIR abnormal signal intensity, for localizing regions of hypercellularity and for monitoring overall tumor status.

Entities:  

Mesh:

Year:  2009        PMID: 19813078      PMCID: PMC2956408          DOI: 10.1007/s11060-009-0018-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Real-time 3D image registration for functional MRI.

Authors:  R W Cox; A Jesmanowicz
Journal:  Magn Reson Med       Date:  1999-12       Impact factor: 4.668

2.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

3.  Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors.

Authors:  F G Barker; S M Chang; S L Huhn; R L Davis; P H Gutin; M W McDermott; C B Wilson; M D Prados
Journal:  Cancer       Date:  1997-09-01       Impact factor: 6.860

4.  How often are nonenhancing supratentorial gliomas malignant? A population study.

Authors:  J N Scott; P M A Brasher; R J Sevick; N B Rewcastle; P A Forsyth
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

5.  Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas.

Authors:  M C Chamberlain; J A Murovic; V A Levin
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

6.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Authors:  T L Chenevert; L D Stegman; J M Taylor; P L Robertson; H S Greenberg; A Rehemtulla; B D Ross
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

7.  The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series.

Authors:  L E Ginsberg; G N Fuller; M Hashmi; N E Leeds; D F Schomer
Journal:  Surg Neurol       Date:  1998-04

8.  Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma.

Authors:  Damien Galanaud; Olivier Chinot; François Nicoli; Sylviane Confort-Gouny; Yann Le Fur; Maryline Barrie-Attarian; Jean-Philippe Ranjeva; Stéphane Fuentès; Patrick Viout; Dominique Figarella-Branger; Patrick J Cozzone
Journal:  J Neurosurg       Date:  2003-02       Impact factor: 5.115

9.  Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

Authors:  Daniel A Hamstra; Craig J Galbán; Charles R Meyer; Timothy D Johnson; Pia C Sundgren; Christina Tsien; Theodore S Lawrence; Larry Junck; David J Ross; Alnawaz Rehemtulla; Brian D Ross; Thomas L Chenevert
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

10.  Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma.

Authors:  D Kondziolka; L D Lunsford; A J Martinez
Journal:  J Neurosurg       Date:  1993-10       Impact factor: 5.115

View more
  9 in total

1.  Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Taryar Zaw; Albert Lai; Phioanh L Nghiemphu; Robert Harris; Shadi Lalezari; Naveed Wagle; Kourosh M Naeini; Jose Carrillo; Linda M Liau; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-01-22       Impact factor: 12.300

2.  Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-12-28       Impact factor: 12.300

3.  Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Paul S Mischel; Phioanh L Nghiemphu; Shadi Lalezari; Kathleen M Schmainda; Whitney B Pope
Journal:  Neuro Oncol       Date:  2011-08-19       Impact factor: 12.300

4.  Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.

Authors:  Benjamin M Ellingson; Mark G Malkin; Scott D Rand; Pete S LaViolette; Jennifer M Connelly; Wade M Mueller; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2010-08-27       Impact factor: 4.130

5.  Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.

Authors:  Craig J Galbán; Thomas L Chenevert; Charles R Meyer; Christina Tsien; Theodore S Lawrence; Daniel A Hamstra; Larry Junck; Pia C Sundgren; Timothy D Johnson; Stefanie Galbán; Judith S Sebolt-Leopold; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2011-04-28       Impact factor: 12.531

6.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

7.  Presentation patterns and outcome of gliomatosis cerebri.

Authors:  Gustavo G Rajz; Dvora Nass; Elisa Talianski; Raphael Pfeffer; Roberto Spiegelmann; Zvi R Cohen
Journal:  Oncol Lett       Date:  2011-10-18       Impact factor: 2.967

8.  Gliomatosis cerebri: clinical characteristics, management, and outcomes.

Authors:  Selby Chen; Shota Tanaka; Caterina Giannini; Jonathan Morris; Elizabeth S Yan; Jan Buckner; Daniel H Lachance; Ian F Parney
Journal:  J Neurooncol       Date:  2013-01-23       Impact factor: 4.130

Review 9.  Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

Authors:  Whitney B Pope; Jonathan R Young; Benjamin M Ellingson
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.